Balagra Kasim Sumabe

Mr. Balagra Kasim Sumabe

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2020 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
ANAina Nedal
Aina Nedal
SRSynnøve Ræder
Synnøve Ræder
BDBjørn Dalhus
Bjørn Dalhus
EHEmily Helgesen
Emily Helgesen
RFRune J Forstrøm
Rune J Forstrøm
MOMarit Otterlei
Marit Otterlei
In the fight against antimicrobial resistance, the bacterial DNA sliding clamp, β-clamp, is a promising drug target for inhibition of DNA replication and translesion synthesis. The β-clamp and its eukaryotic homolog, PCNA, share a C-terminal hydrophobic pocket where all the DNA polymerases bind. Here we report that cell penetrating peptides containing the PCNA-interacting motif APIM (APIM-peptides) inhibit bacterial growth at low concentrations in vitro, and in vivo in a bacterial skin infection model in mice. Surface plasmon resonance analysis and computer modeling suggest that APIM bind to the hydrophobic pocket on the β-clamp, and accordingly, we find that APIM-peptides inhibit bacterial DNA replication. Interestingly, at sub-lethal concentrations, APIM-peptides have anti-mutagenic activities, and this activity is increased after SOS induction. Our results show that although the sequence homology between the β-clamp and PCNA are modest, the presence of similar polymerase binding pockets in the DNA clamps allows for binding of the eukaryotic binding motif APIM to the bacterial β-clamp. Importantly, because APIM-peptides display both anti-mutagenic and growth inhibitory properties, they may have clinical potential both in combination with other antibiotics and as single agents.

10 January 2014 in British Journal of Pharmaceutical Research
Verified
Journal Article
Open access
PDF file
OAOseni Lateef Adebayo
Oseni Lateef Adebayo
AJAbugri James
Abugri James
BSBalagra Kasim Sumabe
Balagra Kasim Sumabe
OJOnilimor Peter Jagri
Onilimor Peter Jagri
Aims: The current study was aimed at evaluating the phytochemical profile and in vitro bacteria growth inhibitory potential of different solvent leaf extracts of V. amygdalina from northern Ghana. Study Design: Different solvent extracts of the plant were quantitatively and qualitatively evaluated for phytochemicals. In vitro bacteria sensitivity assay of the extracts was evaluated using some beta-lactamase producing bacteria as test microbes. Methodology: Ethanolic, methanolic, petroleum ether and aqueous leaf extracts of Vernonia amygdalina were studied in vitro for growth inhibition against beta-lactamase producing bacteria such as Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae and Pseudomonas aeruginosa using agar well diffusion method. Saponins, flavonoids, glycosides, alkaloids, tannins, phenolics, reducing sugars, anthracenosides, terpenes and phytosteroids were determined qualitatively and quantified. Results: All the phytochemicals tested were found to be present in both the methanolic and ethanolic leaf extracts. The aqueous extract showed the presence of saponins, reducing sugars and anthracenosides. Glycosides, flavonoids, saponins and alkaloids were the only groups of phytochemicals found in the petroleum ether extract. The methanolic extract showed the greatest amount of saponins (14.23%), flavonoids (2.15%), alkaloids (7.49%), tannins (5.4%), terpenes (10.20%) and phenolics (8.24%). The methanolic extract at concentration of 4 mg/ml showed growth inhibitory activities against all the test organisms with zone of inhibitions ranging from 16.00+0.50 (against E. coli) to 20.50+0.03 mm (against S. aureus). The ethanolic extract showed activity against only two of the test organisms viz. 23.00+0.33 mm against P. aeruginosa and 12.00+0.00 mm against S. aureus at similar concentration. All test organisms were resistant to both aqueous and pet ether extracts. Conclusion: The antibacterial activities of the methanolic and ethanolic extracts were significant (P < 0.05) and may be mediated by the presence of saponins, flavonoids, tannins, terpenes and alkaloids. Results from present study corroborate previous findings and also presents methanolic leaf extract of the plant as a credible candidate for the discovery of new phytotherapeutic agents against the beta-lactamase producing bacteria tested.

6 January 2024 in BioMed Research International
Verified
Journal Article
Open access
PDF file
ETEdward Jenner Tettevi
Edward Jenner Tettevi
DKDeryl Nii Okantey Kuevi
Deryl Nii Okantey Kuevi
BSBalagra Kasim Sumabe
Balagra Kasim Sumabe
DSDavid Larbi Simpong
David Larbi Simpong
MMMahmoud B Maina
Mahmoud B Maina
AOAugustine Ocloo
Augustine Ocloo
Introduction. Alzheimers disease (AD) is a neurodegenerative disorder with no conclusive remedy. Yohimbine, found in Rauwolfia vomitoria, may reduce brain inflammation by targeting tumour necrosis factor-alpha (TNFα), implicated in AD pathogenesis. Metoserpate, a synthetic compound, may inhibit TNFα. The study is aimed at assessing the potential utility of repurposing metoserpate for TNFα inhibition to reduce neuronal damage and inflammation in AD. The development of safe and effective treatments for AD is crucial to address the growing burden of the disease, which is projected to double over the next two decades. Methods. Our study repurposed an FDA-approved drug as TNFα inhibitor for AD management using structural similarity studies, molecular docking, and molecular dynamics simulations. Yohimbine was used as a reference compound. Molecular docking used SeeSAR, and molecular dynamics simulation used GROMACS. Results. Metoserpate was selected from 10 compounds similar to yohimbine based on pharmacokinetic properties and FDA approval status. Molecular docking and simulation studies showed a stable interaction between metoserpate and TNFα over 100ns (100000ps). This suggests a reliable and robust interaction between the protein and ligand, supporting the potential utility of repurposing metoserpate for TNFα inhibition in AD treatment. Conclusion. Our study has identified metoserpate, a previously FDA-approved antihypertensive agent, as a promising candidate for inhibiting TNFα in the management of AD.

5 June 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
BSBalagra Kasim Sumabe
Balagra Kasim Sumabe
SRSynnøve Ræder
Synnøve Ræder
LRLisa Marie Røst
Lisa Marie Røst
ASAnimesh Sharma
Animesh Sharma
EDEric Donkor
Eric Donkor
MOMarit Otterlei
Marit Otterlei
Drugs targeting DNA and RNA in mammalian cells or viruses can also affect bacteria present in the host and thereby induce the bacterial SOS system. This has the potential to increase mutagenesis and the development of antimicrobial resistance (AMR). Here, we have examined nucleoside analogues (NAs) commonly used in anti-viral and anti-cancer therapies for potential effects on mutagenesis in Escherichia coli, using the rifampicin mutagenicity assay. To further explore the mode of action of the NAs, we applied E. coli deletion mutants, a peptide inhibiting Pol V (APIM-peptide) and metabolome and proteome analyses. Five out of the thirteen NAs examined, including three nucleoside reverse transcriptase inhibitors (NRTIs) and two anti-cancer drugs, increased the mutation frequency in E. coli by more than 25-fold at doses that were within reported plasma concentration range (Pl.CR), but that did not affect bacterial growth. We show that the SOS response is induced and that the increase in mutation frequency is mediated by the TLS polymerase Pol V. Quantitative mass spectrometry-based metabolite profiling did not reveal large changes in nucleoside phosphate or other central carbon metabolite pools, which suggests that the SOS induction is an effect of increased replicative stress. Our results suggest that NAs/NRTIs can contribute to the development of AMR and that drugs inhibiting Pol V can reverse this mutagenesis.